Promoter status | HRM | MSP | PSQ |
---|---|---|---|
Methylated MGMT promoter | |||
 Progression-free survival | |||
  Median duration (months) | 6.0 (3.64–8.36) | 4.4 (3.09–5.72) | 4.6 (2.88–6.32) |
  Rate at 6 months (%) | 51.9 | 40.0 | 46.7 |
 Overall survival | |||
  Median duration (months) | 14.0 (6.50–21.50) | 11.0 (8.19–13.81) | 11.0 (0.27–21.74) |
  Rate at 18 months (%) | 48.1 | 40.0 | 46.7 |
Unmethylated MGMT promoter | |||
 Progression-free survival | |||
  Median duration (months) | 4.0 (3.80–4.20) | 4.2 (3.67–4.73) | 4.0 (3.67–4.33) |
  Rate at 6 months (%) | 31.6 | 40.0 | 34.3 |
 Overall survival | |||
  Median duration (months) | 10.0 (5.03–14.97) | 12.0 (7.36–16.64) | 11.0 (7.62–14.38) |
  Rate at 18 months (%) | 23.7 | 31.1 | 22.9 |